Compare Huntington Ingalls Industries Inc (HII) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 5.6× Huntington Ingalls Industries Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| HII | TAK | |
|---|---|---|
Market Cap | $10.44B | $58.74B |
Volume | 440,462 | 3,110,994 |
Sector | Industrials | Health |
52-Week High | $453.73 | $19.05 |
52-Week Low | $257.05 | $13.23 |
Typical Hold Time | 28 Days | 1 Days |
Enterprise Value | $13.37B | $86.65B |
Dividend Yield | 2.08% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.80, up 1.58% today, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 15.78, net income margin of 5.01%, and a $57.3 billion backlog supporting revenue visibility. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, highlight operational momentum amid consistent earnings beats.
The outlook is supported by strong defense budgets and execution, but risks include project delays and macroeconomic pressures. Analysts are generally positive with a $363.67 consensus target, implying significant upside, though technical indicators suggest near-term caution.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
